Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
Open Access
- 5 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (9) , e014347
Abstract
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors ( PCSK 9i) are used to reduce low‐density lipoprotein ( LDL ) cholesterol. PCSK 9i use after initiation, as well as persistence with or alterations to other LDL ‐lowering therapy after PCSK 9i initiation, is not well understood. Methods and Results: We conducted a retrospective study of alirocumab or evolocumab ( PCSK 9i) new users from July 2015 to December 2017 in the MarketScan Early View database of US commercial insurance beneficiaries. We determined the prevalence of PCSK 9i interruption (≥30‐day gap in supply) and LDL ‐lowering therapy use in the year after PCSK 9i initiation. The average age of 6151 patients initiating PCSK 9i therapy was 63 years, 44.4% were women, and 76.8% had atherosclerotic cardiovascular disease. Overall, 52.2% (95% CI , 50.8%–53.7%) of patients had an interruption in PCSK 9i therapy in the first year after treatment initiation and 62.5% remained on PCSK 9i therapy at 1‐year postinitiation. Also, 27.7% of patients were taking a statin at the time of PCSK 9i initiation, with only 22.4% on statin therapy at 1 year after PCSK 9i initiation. Ezetimibe use decreased from 20.9% at the time of PCSK 9i initiation to 12.0% a year later. By 1 year after PCSK 9i initiation, 44.0% of patients had experienced an interruption in all LDL ‐lowering therapies, and 26.6% were no longer on any LDL ‐lowering therapies. Conclusions: After PCSK 9i initiation, statins were often discontinued, whereas more than half of patients experienced an interruption in PCSK 9i therapy. These results suggest that many new PCSK 9i users may remain at high risk for cardiovascular events because of interruptions in LDL ‐lowering therapy.Keywords
This publication has 25 references indexed in Scilit:
- Agreement between Medicare pharmacy claims, self‐report, and medication inventory for assessing lipid‐lowering medication usePharmacoepidemiology and Drug Safety, 2016
- Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines RegistryAmerican Heart Journal, 2015
- Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS studyAmerican Heart Journal, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trialEuropean Heart Journal, 2015
- Geographic Variation in Statin Use for Complex Acute Myocardial Infarction PatientsMedical Care, 2014
- How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?Current Atherosclerosis Reports, 2012
- Physician Follow-up and Provider Continuity Are Associated With Long-term Medication AdherenceArchives of internal medicine (1960), 2007
- Gaps in Treatment Among Users of Osteoporosis Medications: The Dynamics of NoncomplianceThe American Journal of Medicine, 2007